患者的机会成本与直接成本数据集
斯威士兰耐多药结核病两种门诊护理模式的成本-后果分析数据集,包含健康系统、患者及护理人员的直接与间接成本。

基本信息
资源简介
患者的机会成本与直接成本数据集
【数据集背景】
本数据集源站标题为《Opportunity costs and direct costs for patients.》。源站首次发布:2024-04-02。
【数据内容】
源站原始描述:Background We compared the cost-consequence of a home-based multidrug-resistant tuberculosis (MDR-TB) model of care, based on task-shifting of directly observed therapy (DOT) and MDR-TB injection administration to lay health workers, to a routine clinic-based strategy within an established national TB programme in Eswatini. Methods Data on costs and effects of the two ambulatory models of MDR-TB care was collected using documentary data and interviews in the Lubombo and Shiselweni regions of Esw…
【数据结构与技术规格】
文件数 1 个,合计 5.63 KB。Table 5.xls:application/vnd.ms-excel,5.63 KB。数据集 DOI:10.1371/journal.pone.0301507.t005。
【主题与分类】
源站学科分类:Medicine、Biotechnology、Environmental Sciences not elsewhere classified、Ecology、Cancer、Science Policy。主题标签:using standard methods、pocket travel expenses、directly observed therapy、20 007 ).、treatment support components、treatment success rates、public health outcomes、lay health workers、generated substantial health、xlink "> data。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面:https://plos.figshare.com/articles/dataset/Opportunity_costs_and_direct_costs_for_patients_/25528333
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:Peresu, Ernest; De Graeve, Diana; Heunis, J. Christo; Kigozi, N. Gladys (2024). Opportunity costs and direct costs for patients.. PLOS ONE. Dataset
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:Opportunity costs and direct costs for patients.
- DOI:10.1371/journal.pone.0301507.t005
- 发布日期:2024-04-02
- 文件数:1 个
- 文件总体积:5.63 KB
- 源站页面:https://plos.figshare.com/articles/dataset/Opportunity_costs_and_direct_costs_for_patients_/25528333
命令行下载
curl -L -o "Table 5.xls" "https://ndownloader.figshare.com/files/45420550"
文件清单
Table 5.xls(5.63 KB)
文件总体积 5.63 KB(源站 API 实测)。
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
Background
We compared the cost-consequence of a home-based multidrug-resistant tuberculosis (MDR-TB) model of care, based on task-shifting of directly observed therapy (DOT) and MDR-TB injection administration to lay health workers, to a routine clinic-based strategy within an established national TB programme in Eswatini.
Methods
Data on costs and effects of the two ambulatory models of MDR-TB care was collected using documentary data and interviews in the Lubombo and Shiselweni regions of Eswatini. Health system, patient and caregiver costs were assessed in 2014 in US$ using standard methods. Cost-consequence was calculated as the cost per patient successfully treated.
Results
In the clinic-based and home-based models of care, respectively, a total of 96 and 106 MDR-TB patients were enrolled in 2014, with treatment success rates of 67.8% and 82.1%. Health system costs per patient treated were slightly lower in the home-based strategy (US$19 598) compared to the clinic-based model (US$20 007). The largest costs in both models were for inpatient care, administration of DOT and injectable treatment, and drugs. Costs incurred by patients and caregivers were considerably higher in the clinic-based model of care due to the higher direct travel costs to the nearest clinic to receive DOT and injections daily. In total, MDR patients in the clinic-based strategy incurred average costs of US$670 compared to US$275 for MDR-TB patients in the home-based model. MDR-TB patients in the home-based programme, where DOT and injections was provided in their homes, only incurred out-of-pocket travel expenses for monthly outpatient treatment monitoring visits averaging US$100. The cost per successfully treated patient was US$31 106 and US$24 157 in the clinic-based and home-based models of care, respectively. The analysis showed that, in addition to the health benefits, direct and indirect costs for patients and their caregivers were lower in the home-based care model.
Conclusion
The home‐based strategy used less resources and generated substantial health and economic benefits, particularly for patients and their caregivers, and decision makers can consider this approach as an alt
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.1371/journal.pone.0301507.t005(source: https://plos.figshare.com/articles/dataset/Opportunity_costs_and_direct_costs_for_patients_/25528333)。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




